JP Morgan Chase’s Agios Pharmaceuticals AGIO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$888K Hold
30,000
﹤0.01% 4680
2025
Q4
$817K Buy
+30,000
New +$1.05M ﹤0.01% 4734
2023
Q1
Sell
-208,600
Closed -$5.86M 6650
2022
Q4
$5.86M Buy
+208,600
New +$5.88M ﹤0.01% 2692
2020
Q2
Sell
-55,000
Closed -$1.95M 5336
2020
Q1
$1.95M Buy
+55,000
New +$2.54M ﹤0.01% 2983
2019
Q3
Sell
-67,100
Closed -$3.33M 5689
2019
Q2
$3.33M Sell
67,100
-7,900
-11% -$422K ﹤0.01% 2983
2019
Q1
$5.06M Buy
+75,000
New +$4.37M ﹤0.01% 2572
2018
Q4
Sell
-30,000
Closed -$2.31M 5662
2018
Q3
$2.31M Buy
+30,000
New +$2.41M ﹤0.01% 3352

Other funds holding AGIO

JP Morgan Chase's AGIO Position: Q1 2026 in Review

JP Morgan Chase reduced its Agios Pharmaceuticals (AGIO) stake by 40% in Q1 2026, selling an estimated $2.84M and leaving 151,558 shares worth $4.49M. The position accounts for ﹤0.01% of the portfolio, ranked #3418.

JP Morgan Chase first reported a position in AGIO in Q3 2013 and has held it in 51 quarters since. The position peaked at $284M in Q2 2021. 233 funds tracked by Wall St. Rank hold AGIO as of Q1 2026.

  • JP Morgan Chase held 151,558 shares of Agios Pharmaceuticals worth $4.49M as of Q1 2026.
  • JP Morgan Chase sold 100,219 Agios Pharmaceuticals shares in Q1 2026, an estimated $2.84M.
  • Agios Pharmaceuticals made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #3418 holding.
  • JP Morgan Chase first reported a position in Agios Pharmaceuticals in Q3 2013 and has held it in 51 quarters since.
  • JP Morgan Chase's Agios Pharmaceuticals position peaked at $284M in Q2 2021.
  • 233 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.